Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors

For patient having a brain tumor, RMI is the standard exam for tumor characterization and determines initial surgery.

The aim of this study is to assess if PET could provide additional information that could have an impact on surgery (indication and planification)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Brain Neoplasms Adult Brain Tumor Brain Diseases Central Nervous System Diseases Central Nervous System Neoplasms Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Eugène Marquis

Rennes, Brittany Region, 35042, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Suspected glial resectable tumor
Free and informed consent
Affiliated to French social security

Exclusion criteria

Suspected high grade glioma
Surgical emergency
Pregnant or breastfeeding woman
Patient deprived of their liberty or under guardianship
Patient not able to follow study medical monitoring for geographical, social or psychological reasons
Treated with carbidopa, catechol-O-methyl transferase inhibitor, haloperidol, reserpine within 2 weeks before PET imagery

Treatment and study plan

PET imagery

Diagnostic Test

Every patients will have a PET imagery in addition to standard MRI

Primary outcomes

PET pictures and MRI sequences comparison

Time frame: Imagings performed up to 29 days after inclusion (before brain surgery)

Comparison of PET pictures and MRI sequences will be done in order to assess concordance between both imagings

Sponsors and collaborators

Lead sponsor

Center Eugene Marquis

Other

Registry information

Official study title

Diagnostic Assessment Study, Single Site and Prospective, comparing18F-DOPA PET and Multiparametric RMI in Initial Exploration of Diffuse Glial Tumors

Acronym: GLIROPA

Important dates

Study start: 2018
Primary completion: 2019
Study completion: 2019
First posted: May 15, 2018
Registry last updated: Jan 27, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed